Literature DB >> 3440103

Determination of debrisoquine metabolic ratio from hourly urine collections in healthy volunteers.

P A Philip1, C A James, H J Rogers.   

Abstract

The possibility of simplifying the regimen for the collection of urine samples in the determination of the debrisoquine metabolic ratio (DMR) was explored in 15 normal subjects. In the extensive metaboliser subgroup (EM; n = 11), there was a close correlation between the DMR as determined by an 8 h urine collection and the debrisoquine/4-hydroxydebrisoquine ratio (D/4-OHD) in the hourly samples (excluding the first hour). In the poor metabolisers (PM; n = 4) the phenotype could be identified, but it was not possible to estimate the DMR reliably.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3440103      PMCID: PMC1386412          DOI: 10.1111/j.1365-2125.1987.tb03254.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  Pharmocogenetic implications of polymorphic debrisoquine hydroxylations.

Authors:  M D Rawlins
Journal:  Q J Med       Date:  1985-02

2.  Why hypertensive patients vary in their response to oral debrisoquine.

Authors:  J H Silas; M S Lennard; G T Tucker; A J Smith; S L Malcolm; T R Marten
Journal:  Br Med J       Date:  1977-02-12

3.  Genetically determined oxidation capacity and the disposition of debrisoquine.

Authors:  T P Sloan; R Lancaster; R R Shah; J R Idle; R L Smith
Journal:  Br J Clin Pharmacol       Date:  1983-04       Impact factor: 4.335

Review 4.  Defective oxidation of drugs: pharmacokinetic and therapeutic implications.

Authors:  M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

5.  Some observations on the oxidation phenotype status of Nigerian patients presenting with cancer.

Authors:  J R Idle; A Mahgoub; T P Sloan; R L Smith; C O Mbanefo; E A Bababunmi
Journal:  Cancer Lett       Date:  1981-02       Impact factor: 8.679

6.  Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver.

Authors:  D S Davies; G C Kahn; S Murray; M J Brodie; A R Boobis
Journal:  Br J Clin Pharmacol       Date:  1981-01       Impact factor: 4.335

7.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

Authors:  D A Evans; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1980-04       Impact factor: 6.318

Review 8.  Genetic variation in the human hepatic cytochrome P-450 system.

Authors:  W Kalow
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

9.  Metabolic oxidation phenotypes as markers for susceptibility to lung cancer.

Authors:  R Ayesh; J R Idle; J C Ritchie; M J Crothers; M R Hetzel
Journal:  Nature       Date:  1984 Nov 8-14       Impact factor: 49.962

10.  Polymorphic hydroxylation of Debrisoquine in man.

Authors:  A Mahgoub; J R Idle; L G Dring; R Lancaster; R L Smith
Journal:  Lancet       Date:  1977-09-17       Impact factor: 79.321

View more
  1 in total

1.  Debrisoquine oxidation phenotype and susceptibility to lung cancer.

Authors:  A R Boobis; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.